Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pentoxifylline Therapy in Biliary Atresia
NCT01774487 · Baylor College of Medicine · PHASE2 · terminated · last registry update 2024-01-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Target enrollment was not reached because the medication, pentoxifylline, has a taste that is not well tolerated by infants. The study team decided to end the study before meeting the enrollment goal because of the medication taste.” | – | Registry record, Baylor College of Medicine |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ADORA2B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-10-01Results posted on the registry: Philips Clinical & Medical Affairs Global, a drug against ADORA2B (NCT04696354)
- 2024-08-13Phase 3 first posted: University of Illinois Chicago, a drug against ADORA2B (NCT06550804)
- 2024-07-30Results posted on the registry: Seagen, a wholly owned subsidiary of Pfizer, tucatinib + placebo (NCT03975647)
- 2024-06-18Phase 3 first posted: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Cladribine Low Dose + Cladribine High Dose (NCT06463587)
- 2024-05-06Results posted on the registry: University of Maryland, Baltimore, Clopidogrel + Ticagrelor (NCT03161678)
- 2024-04-08Phase 3 first posted: The George Institute, Standard-dose intravenous tenecteplase + Low-dose intravenous tenecteplase (NCT06352632)
- 2023-12-05Results posted on the registry: City of Hope Medical Center, 8-Chloroadenosine (NCT02509546)
- 2023-11-13Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., SHR-A1811 + Trastuzumab Emtansine (NCT06126640)
- 2023-11-02Phase 3 first posted: University of Utah, a drug against ADORA2B (NCT06112990)
- 2023-06-02Phase 3 first posted: University of Leicester, Low calorie meal replacement plan (NCT05887271)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision